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Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is extensively
explored in cancers. It functions as an important regulator of cell growth, survival and metabolism. Activation of
this pathway also predicts poor prognosis in numerous human malignancies. Drugs targeting this signaling
pathway have been developed and have shown preliminary clinical activity. Accumulating evidence has
highlighted the important role of PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and
progression. Therapeutic functions of PI3K inhibitors in NHL have been demonstrated both in vivo and in vitro.
This review will summarize recent advances in the activation of PI3K signaling in different types of NHL and the
applications of PI3K inhibitors in NHL treatment.
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The PI3K/Akt/mTOR pathway plays a critical role in
regulating cancer cell growth, survival, motility and me-
tabolism [1]. Phosphatidylinositol 3-kinase (PI3K) is a
critical element in this signaling, it is activated in a wide
range of human neoplasms and associated with poor
outcomes [2,3]. Our previous studies have demonstrated
that down regulation of heat shock protein 70 (HSP70)
contributed to the increased sensitivity of Burkitt lymph-
oma (BL) cells to chemotherapy through blocking this
pathway [4]. Targeted inhibitors for PI3K signaling are
opening a new paradigm in cancer treatment. Activation
of this pathway was identified in different types of NHL
[5]. A number of PI3K inhibitors have been developed
and displayed preliminary clinical activities in NHL
treatment.
The PI3K signaling pathway in cancer
The PI3K signaling pathway is triggered by activation of
receptor tyrosine kinase (RTK) in cell membrane. After
binding to the growth factors, the intracellular domain of
RTK is phosphorylated, and PI3K is activated (Figure 1).
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stated.PI3Ks as the most studied in human cancer [6]. Activated
PI3K phosphorylates PI(4,5)P2 (PIP2) to produce PI(3,4,5)
P3 (PIP3). The tumor suppressor phosphatase and tensin
homolog (PTEN) deleted on chromosome ten could nega-
tively regulate this process through dephosphorylating
PIP3. Activated PIP3 could prompt the phosphorylation of
Akt and further stimulate the Aktmediated activation of
downstream targets, including the Bcl-2 family members,
Mdm2 and tuberous sclerosis complex 2 (TSC2) [7]. Acti-
vated Akt inhibits the Rheb GTPase activity of TSC1/2
complex through phosphorylating TSC2. Then the acti-
vated Rheb promotes mTOR complex 1 (mTORC1) to
phosphorylate p70S6 and 4E binding protein1 (4EBP1),
resulting in dysregulation of protein synthesis and cell sur-
vival [8]. On the other hand, mTORC2, another type of
mTOR complex, could phosphorylate Akt on serine 473
and facilitate its complete activation [9].
The PI3K/Akt/mTOR pathway is constitutively acti-
vated in human cancers and is critical for tumor progres-
sion and chemo-resistance [10]. Alterations of several
components in this pathway have been identified in nu-
merous tumors [11]. Mutation of PI3KA was most com-
monly recognized in breast, colorectal and endometrial
cancers [12]. And the alteration of Akt was found in gas-
tric, pancreatic and ovarian cancers. These alterations
promoted the development of PI3K pathway-specific
inhibitors [7]. Several PI3K pathway inhibitors haved. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 The PI3K/Akt/mTOR pathway and relative inhibitors in NHL. Once RTKs binding to the growth factors, the PI3K signaling pathway
is triggered. Activated PI3K could phosphorylate PI (4,5) P2 (PIP2) to produce PI(3,4,5)P3 (PIP3). This process is negatively regulated by PTEN. Akt
inhibits the Rheb GTPase activity of TSC1/TSC2 dimer by phosphorylating TSC2. Then activated Rheb stimulates mTOR to phosphorylate the
p70S6 and 4E-binding protein (4EBP-1), resulting in dysregulation of protein synthesis and cell survival. On the other hand, mTORC2, another type
of mTOR complex, could phosphorylate Akt and promote the complete activation of it.
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clinical studies. As PI3K/Akt/mTOR pathway plays a key
role in the proliferation and survival of lymphoma cell,
various inhibitors targeting this pathway have been stud-
ied in different types of NHL (Table 1). In spite of preclin-
ical studies, several PI3K inhibitors for NHL treatment are
currently undergoing various stages of clinical trials
(Table 2) [13]. Here we will focus on the clinical develop-
ment of PI3K inhibitors for NHL.Table 1 Different PI3K pathway inhibitors in NHL
Inhibitors Targets Lymphoma
type
References
NVP-BEZ235 Dual PI3K and mTOR FL, DLBCL,
MCL,T-ALL
[14-17]
CAL-101 Isoform-specific
PI3K(δ)
CLL, MCL [18,19]
NVP-BKM120 Pan-isoform PI3K B-CLL, DLBCL [20,21]
LY294002 Pan-isoform PI3K DLBCL, MCL,
BL, T-ALL
[22-25]
GDC-0941 Pan-isoform PI3K MCL, T-cell
lymphoma
[26,27]
RAD001 mTOR MCL [28]
PI-103 Dual PI3K and mTOR BL, T-ALL [25,29]PI3K inhibitors in follicular lymphoma
Follicular lymphoma (FL) is one of the most common
types of indolent NHL. In spite of its indolent phase,
about 25%-60% of them eventually transform into diffuse
large cell lymphoma (DLBCL), a type of aggressive lymph-
oma. Combination therapy included rituximab cannot sig-
nificantly decline the relapse rate of FL [14]. Therefore,
novel effective therapeutic agents are urgently needed to
improve the outcomes of FL patients.
Gulmann C et al. demonstrated the activation of
PI3K/Akt/mTOR pathway in FL by proteomic analysis
[30]. They provided evidence that activation and phos-
phorylation of PI3K as well as its downstream effec-
tors, including Akt, mTOR, and S6K, were found in
FL. Recently, a PI3K/mTOR module was reported to
mediate the invasion and angiogenesis of FL, which
further confirmed its potential use in anti-invasive of
FL [31]. NVP-BEZ235, a dual PI3K and mTOR inhibi-
tor, was indicated to be effective in inhibiting FL cell
proliferation [14]. Proliferation of FL cell line was sub-
stantially inhibited by NVP-BEZ235, activation level of
caspase-3 increased by 1.6 to 2 fold in NVP-BEZ235-
treated cells compared to that treated with vehicle
alone [14]. In addition, anti-tumor function and the
therapeutic potential of NVP-BEZ235 were also identi-
fied in other human malignancies, such as T-cell acute
Table 2 PI3K pathway inhibitors in clinical development for NHL treatment
Drugs Target Clinical trial phase NHL type NCT no.
Pan-isoform PI3K inhibitor
NVP-BKM120 Class I PI3K II (recruiting) Relapsed and refractory NHL (DLBCL, MCL or FL) NCT01693614
GDC-0941 Class I PI3K I (completed) NHL NCT00876122
BAY80-6946 Class I PI3K II (recruiting) Relapsed, indolent or aggressive NHL (FL, MALT lymphoma,
CLL, LPL/WM, DLBCL, MCL, peripheral T-cell lymphoma, ALCL)
NCT01660451
Isoform specific PI3K inhibitor
CAL-101 (GS-1101) p110δ III (recruiting) Previously treated indolent NHL (FL, SLL, LPL/WM, MZL) NCT01732913
I/II (recruiting) Previously treated low-grade (indolent) B-cell NHL (FL, SLL, MZL) NCT01306643
IPI-145 p110γ/δ II (recruiting) Refractory indolent NHL (FL, MZL, or SLL) NCT01882803
I (recruiting) Relapsed/refractory hematologic malignancies (NHL, CLL, T-cell
lymphoma)
NCT01871675
Dual PI3K/mTOR inhibitor
NVP-BEZ235 PI3K/mTOR I (recruiting) relapsed or refractory acute leukemia (ALL, AML, CML-BP) NCT01756118
Allosteric mTOR inhibitor
RAD001 mTOR I/II (recruiting) NHL NCT01567475
I/II (recruiting) relapsed or refractory NHL or HL NCT01075321
II (completed) Relapsed or Refractory DLBCL NCT00869999
MALT, mucosa-associated lymphoid tissue; LPL/WM, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; SLL, small lymphocytic lymphoma;
MZL, marginal zone lymphoma; AML, acute myeloid leukemia; CML-BP, chronic myeloid leukemia in blastic phase.
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cancer [15,32,33].The roles in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most
common type of adult leukemia in the western world,
with 15,000 new cases and approximately 4,500 deaths per
year [34]. It is characterized by accumulation of malignant
B cells in the blood, bone marrow and secondary lymph-
oid tissues [35]. Novel targeted agents and potential thera-
peutic options have been provided recently [36,37].
Consistent expressions of PI3K-δ were found in both
primary CLL cells and normal B cells, but the CLL cells
represented a statistically higher intrinsic PI3K activity
compared to normal B cells [18,38]. CAL-101 (GS-1101)
is a specific inhibitor of PI3K-δ isoform. It could prevent
the proliferation and induce apoptosis of CLL cells through
disrupting multiple external pathways. Activation of Akt,
and secretion of cytokines and chemokines were inhibited
by CAL-101 in both vitro and vivo [18,39,40]. B cells from
16 CLL patients were treated with CAL-101 at different
concentrations for 48 hours [18]. The results showed that
CAL-101 promoted CLL cells apoptosis in a dose- and
time-dependent pattern.
Coutre et al. have reported a phase I study using CAL-
101 as a single agent for relapsed/refractory CLL pa-
tients [41]. About 80% of them achieved >50% reduction
in the size of lymph node and spleen. On the contrary,
approximately >50% increase in lymphocytosis of peripheralblood occurred in 58% patients. This trial also provided evi-
dence of limited toxicity of CAL-101 in CLL treatment [41].
A phase I study of CAL-101 in combination with rituximab
or bendamustine in 20 patients with relapsed/refractory
B-cell malignancies (indolent B-cell NHL n = 12, CLL
n = 8) reached the same conclusion as well. The main ad-
verse effects, Grade 3 neutropenia and thrombocytopenia,
were found in 22% of patients receiving bendamustine plus
CAL-101. Additionally, the peripheral lymphocyte counts
were stable or decreased in 8/8 CLL patients after com-
bination treatment [42].
NVP-BKM120 is an orally available pan class I inhibi-
tor of PI3K. It was reported to inhibit the phosphoryl-
ation of Akt in primary B-CLL lymphocytes and further
inhibit the PI3K signaling [20]. NVP-BKM120 also con-
tributed to the concomitant Mcl-1 downregulation and
Bim induction though regulating the Akt/FoxO3a/Bim
axis in CLL [43]. It was 3.6 fold more toxic than CAL-101
in malignant B-CLL lymphocytes in vitro. A study on 65
B-CLL patients revealed that NVP-BKM120 was cytotoxic
in 78% of the primary B-CLL lymphocytes [20].The roles in diffuse large B cell lymphoma
DLBCL represents the most common subtype of NHL.
It accounts for 40% of newly diagnosed NHL in the
world and approximately 40–50% of newly diagnosed
lymphoid neoplasms in China [44,45].
Dysregulation of the PI3K/Akt/mTOR signaling path-
way was observed in DLBCL [46,47]. Xu et al. investigated
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their clinical significance in 73 DLBCL cases [44]. Activation
of this pathway was related to poor treatment response and
decreased survival time in DLBCL patients treated with
CHOP chemotherapy regimen (cyclophosphamide, doxo-
rubicin, vincristine, and prednisone) but not in those treated
with rituximab-CHOP (R-CHOP) [44].
Previous studies have indicated that apoptosis of DLBCL
cell lines could be induced by LY294002, a pan-isoform
PI3K inhibitor [22]. NVP-BEZ235 is a novel dual inhibitor
of PI3K and mTOR. Concurrent inhibition of PI3K and
mTOR by NVP-BEZ235 resulted in the down-regulation
of Eif4e phosphorylation and MCL-1 expression. It could
inhibit the proliferation of DLBCL cells via inhibiting acti-
vation of PI3K, mTORC1 and mTORC2 in both central
B-cell (GCB) and activated B-cell (ABC) subtype of
DLBCL [16]. But when the concentration of NVP-BEZ235
was 0.5 μM or below, the induction response of cell de-
mise in ABC cell lines was less efficient than that in GCB
cell lines.
Recent studies have highlighted that NVP-BKM120, a
pan-class I inhibitor of PI3K/Akt/mTOR signaling path-
way. NVP-BKM120 reduced cell proliferation and increase
the apoptosis of DLBCL cells through blocking the au-
tophagy,as well as up-regulating Puma and Bim and inhi-
biting anti-apoptotic Mcl-1 expression [21]. Additionally,
a phase I and dose-escalation study of NVP-BKM120 pro-
vided evidence of the feasibility of PI3K inhibitors in pa-
tients with advanced solid cancers [48]. Although few of
them were moved into clinical application currently, the
PI3K inhibitors will bring up new therapeutic options for
relapse/refractory DLBCL.
The roles in mantle cell lymphoma
Mantle cell lymphoma (MCL) accounts for about 6% of
all NHL and the median age at diagnosis is about 65. It
is characterized by chromosomal translocation t(11;14)
(q13;q32) resulting in over-expression of cyclin D1,
which are regulated by the Akt/mTOR signaling path-
way [49,50]. Despite the relatively good response to first-
line chemotherapy, most of the MCL patients relapsed
eventually.
Recent studies have revealed the importance of PI3K/
Akt/mTOR signaling pathway and clinical application of
PI3K inhibitors in MCL [51,52]. Gene expression profil-
ing of both purified leukemic MCL cells and the naive
B cells were performed through oligonucleotide micro-
arrays [53]. 106 genes were found to be differentially
expressed at least three fold in MCL cells compared to
naive B cells, with 43 downregulated and 63 upregu-
lated. Several genes relating PI3K/Akt signaling path-
way were found to be aberrantly expressed in MCL
cells compared with naive B cells, such as PIK3CA,
PDK2, PDPK1, AKT1, RPS6KB2, FOXO3A, PPP2R2Cand PDK1 [53]. Moreover, increased gene copy num-
ber ( ≥ 3) of PIK3CA were discovered in 68% of MCL
cases and two MCL cell lines(Rec-1 and GRANTA-
519) [23]. Mutation of PIK3CA gene resulted in consti-
tutive activation of PI3K and the consequent activation
of Akt pathway in MCL. They further investigated the
apoptosis of MCL cell lines treated with LY294002. The
apoptotic rates increased from 3% to 20% in GRANTA-
519 cells and from 7.3% to 20% in Rec-1 cells [23].
RAD001 (everolimus), an mTOR inhibitor, could halt
the translation of proteins critical for cell survival and
proliferation via inhibiting mTOR phosphorylation [54].
Approximately 40 ~ 65% antiproliferative effects was found
in MCL cell lines treated with single agent RAD001 com-
pared with control groups [28]. However, NVP-BEZ235
is more effective than mTOR inhibitors (rapamycin,
RAD001) in inhibiting the downstream pathway of
mTOR and mediating cell death. Further analysis
demonstrated that NVP-BEZ235 could lead to a dose
dependent down-regulation of Mcl-1 protein while
rapamycin could not [55]. Civallero et al. analyzed the
inhibitory effects of NVP-BEZ235 on MCL cell lines
and its effects in combination with enzastaurin, evero-
limus and perifosine [17]. NVP-BEZ235 induced sig-
nificant increase of cell apoptosis in MCL through
both intrinsic and extrinsic pathways. When combined
with enzastaurin, everolimus and perifosine, the NVP-
BEZ235 triggered cytotoxicity was enhanced significantly
[17]. NVP-BEZ235 also showed a much stronger anti-
proliferative function in MCL cells compared to single in-
hibitors of PI3K/mTOR, such as NVP-BKM120 and
RAD001 [56]. Additionally, NVP-BEZ235 could syner-
gistically enhance the cytotoxic function of conven-
tional anti-tumor agents and remarkably overcome the
acquired bortezomib resistance in MCL [56].
CAL-101 was reported to inhibit constitutive activa-
tion of the PI3K/Akt/mTOR pathway and exert potent
antitumor effects across a wide range of B-cell malignan-
cies [39]. Previous studies have demonstrated the func-
tions of CAL-101 in PI3K inhibition and pro-apoptosis
effect in NHL cell lines. A phase I study focused on the
safety and activity of CAL-101 in patients with relapsed/
refractory hematologic malignancies was carried out re-
cently [19]. A total of 55 patients (18 MCL patients in-
cluded) enrolled, CAL-101 was administered orally once
or 2 times per day continuously in a 28-day cycle for up
to 12 cycles. As a consequence, the overall response rate
for MCL was 62% [19]. Nevertheless, GDC-0941, a dual
p110α/δ inhibitor, was more active compared to CAL-
101 in both MCL samples and cell lines [26].
The roles in Burkitt leukemia/lymphoma
Burkitt leukemia/lymphoma (BL) is a highly proliferative
B-cell lymphoma characterized by constitutive MYC
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chemotherapy regimens in BL treatment, less toxic and
more targeted treatment strategies are still needed to
improve BL prognosis, especially in high-risk and re-
lapsed/refractory patients [57,58]. PI3K pathway acts as
a vital determinant in the B cell receptor (BCR)-medi-
ated survival signal in mature, resting B cells [59]. It has
been indicated that the MYC-driven lymphoma is associ-
ated with mTOR activation and an endogenous DNA
damage response transduced by PI3K-related kinase [60].
Activation of PI3K pathway has been found in BL
tissues and cell lines. When treated BL cell lines with
LY-294002, the phosphorylation of Akt kinase was
largely diminished [24]. In drug-resistant Ramos and
Daudi B-NHL cell lines, LY294002 treatment also accounted
for the inhibition of Bcl-(xL) expression and sensitization to
drug-induced apoptosis [61]. Our previous study also
indicated the existence of PI3K/Akt/HSP70 cascade in
Raji cells lines [4]. LY294002 significantly attenuated
Akt activation, resulted in induced cell apoptosis and
increased ADM and DDP sensitivity [4]. PI-103, a dual
PI3K/mTOR inhibitor, was also associated with the
caspase-dependent cleavage of PARP and inhibition of
c-MYC activity in BL cells [29].
The studies of PI3K inhibitors in T-cell lymphoma
Activation of PTEN-PI3K-Akt pathway in T-ALL has been
assessed by array comparative genomic hybridization and
sequence analysis [62]. Alterations of PTEN, PI3K, or Akt
existed in 47.7% of total 44 cases. Moreover, patients with
lymphoblasts harboring PTEN deletions at the time of
diagnosis showed significantly adverse therapeutic conse-
quences [62]. Furthermore, the PI3K transgenic mice
could develop an infiltrating lymphoproliferative disorder
[63]. Lymphomas (67%) and sarcomas (33%) occurred in
p53 knockout mice, however, when p53 deletion was com-
bined with PI3K activation, only lymphomas developed. In
addition, PTEN, a negative regulator of PI3K pathway,
showed decreased expression level in 66.7% of anaplastic
large cell lymphoma (ALCL) cases [64]. And increased ex-
pression of PIK3CD gene (encoding PI3K δ isoform), was
found in peripheral and cutaneous T-cell lymphoma [27].
P110a, p110h, p110g, and p110y isoforms of PI3Ks
were expressed in T-ALL cell lines. A dose-dependent
decrease in cell survival was obtained with p110a PI3K
selective inhibitor. Nevertheless, PI-103 was more effi-
cient in inhibiting T-ALL cell proliferation and inducing
cell apoptosis than inhibitors that are selective only for
PI3K (Wortmannin and LY294002) [25]. The pan-PI3K
inhibitor, GDC-0941, resulted in arrest of all peripheral
and cutaneous T-cell lymphoma cell lines in the G1
phase. When cooperated with MEK inhibitors, GDC-
0941 showed a highly synergistic effect in enhancing cell
cycle arrest in all T-cell lymphoma cell lines [27].Conclusions
In summary, PI3K signaling pathway was activated in
both B-cell and T-cell NHL and involved in the develop-
ment and progression of these diseases. The PI3K inhibi-
tors revealed significant cytotoxicity either alone or in
combination with other agents in lymphocytic cells.
They have promised the breakthrough data and provided
an attractive treatment option for anticancer therapeutic
intervention of NHL. However, further investigations are
still required to get a better understanding of the clinical
benefits of PI3K inhibitors.
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